Cognitive impairment and dementia in Parkinson's disease

Movement Disorders

Volumn 25, Issue SUPPL. 1, 2010, Pages

  Marder, Karen ^a,b,c  

^a Howard Hughes Medical Institute   (United States)

^b Department of Epidemiology   (United States)

^c New York Presbyterian Morgan Stanley Children's Hospital   (United States)

Author keywords

Cognitive impairment; Dementia; Parkinson's disease

Indexed keywords

AMANTADINE; DONEPEZIL; GALANTAMINE; PLACEBO; RIVASTIGMINE; TACRINE;

ARTICLE; CLINICAL TRIAL; DEMENTIA; DISEASE COURSE; ENVIRONMENTAL FACTOR; GENETIC RISK; HUMAN; MILD COGNITIVE IMPAIRMENT; NAUSEA; NEUROIMAGING; NEUROPSYCHOLOGY; PARKINSON DISEASE; PREVALENCE; PRIORITY JOURNAL; RISK ASSESSMENT; TREMOR; VOMITING; COGNITIVE DEFECT; ENVIRONMENT; FEMALE; GENETICS; MALE; NEUROPSYCHOLOGICAL TEST; RISK FACTOR; SEX DIFFERENCE;

COGNITION DISORDERS; DEMENTIA; ENVIRONMENT; FEMALE; HUMANS; MALE; NEUROPSYCHOLOGICAL TESTS; PARKINSON DISEASE; RISK FACTORS; SEX FACTORS;

EID: 77953452502     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.22787     Document Type: Article

References (104)

1. Brown RG, Marsden CD. How common is dementia in Parkinson's disease? Lancet 1984; 2: 1262-1265.
2. Mayeux R, Denaro J, Hemenegildo N, et al. A population-based investigation of Parkinson's disease with and without dementia. Relationship to age and gender. Arch Neurol 1992; 49: 492-497.
3. Aarsland D, Tandberg E, Larsen JP, Cummings JL. Frequency of dementia in Parkinson disease. Arch Neurol 1996; 53: 538-542.
4. Tison F, Dartigues JF, Auriacombe S, Letenneur L, Boller F, Alperovitch AP. Dementia in Parkinson's disease: a population-based study in ambulatory and institutionalized individuals. Neurology 1995; 45: 705-708.
5. Biggins CA, Boyd JL, Harrop FM, et al. A controlled, longitudinal study of dementia in Parkinson's disease. J Neurol Neurosurg Psychiatry 1992; 55: 566-571.
6. Friedman A, Barcikowska M. Dementia in Parkinson's disease. Dementia 1994; 5: 12-16.
7. de Lau LM, Schipper CM, Hofman A, Koudstaal PJ, Breteler MM. Prognosis of Parkinson disease: risk of dementia and mortality: the Rotterdam Study. Arch Neurol 2005; 62: 1265-1269.
8. Aarsland D, Zaccai J, Brayne C. A systematic review of prevalence studies of dementia in Parkinson's disease. Mov Disord 2005; 20: 1255-1263.
9. Marttila RJ, Rinne UKP. Dementia in Parkinson's disease. Acta Neurol Scand 1976; 54: 431-441.
10. Hughes TA, Ross HF, Musa S, et al. A 10-year study of the incidence of and factors predicting dementia in Parkinson's disease. Neurology 2000; 54: 1596-1602.
11. Marder K, Tang MX, Cote L, Stern Y, Mayeux R. The frequency and associated risk factors for dementia in patients with Parkinson's disease. Arch Neurol 1995; 52: 695-701.
12. Aarsland D, Andersen K, Larsen JP, Lolk A, Nielsen H, Kragh-Sorensen PP. Risk of dementia in Parkinson's disease: a community-based, prospective study. Neurology 2001; 56: 730-736.
13. Hobson P, Meara J. Risk and incidence of dementia in a cohort of older subjects with Parkinson's disease in the United Kingdom. Mov Disord 2004; 19: 1043-1049.
14. Williams-Gray CH, Foltynie T, Lewis SJ, Barker RA. Cognitive deficits and psychosis in Parkinson's disease: a review of pathophysiology and therapeutic options. CNS Drugs 2006; 20: 477-505.
15. Aarsland D, Kvaloy JT, Andersen K, et al. The effect of age of onset of PD on risk of dementia. J Neurol 2007; 254: 38-45.
16. Levy G. The relationship of Parkinson disease with aging. Arch Neurol 2007; 64: 1242-1246.
17. Levy G, Schupf N, Tang MX, et al. Combined effect of age and severity on the risk of dementia in Parkinson's disease. Ann Neurol 2002; 51: 722-729.
18. Jankovic J, McDermott M, Carter J, et al. Variable expression of Parkinson's disease: a base-line analysis of the DATATOP cohort.The Parkinson Study Group. Neurology 1990; 40: 1529-1534.
19. Levy G, Tang MX, Cote LJ, et al. Motor impairment in PD: relationship to incident dementia and age. Neurology 2000; 55: 539-544.
20. Burn DJ, Rowan EN, Allan LM, Molloy S, O'Brien JT, McKeith IG. Motor subtype and cognitive decline in Parkinson's disease, Parkinson's disease with dementia, and dementia with Lewy bodies. J Neurol Neurosurg Psychiatry 2006; 77: 585-589.
21. Alves G, Larsen JP, Emre M, Wentzel-Larsen T, Aarsland D. Changes in motor subtype and risk for incident dementia in Parkinson's disease. Mov Disord 2006; 21: 1123-1130.
22. Foltynie T, Brayne CE, Robbins TW, Barker RA. The cognitive ability of an incident cohort of Parkinson's patients in the UK.The CamPaIGN study. Brain 2004; 127 (Part 3): 550-560.
23. Breteler MM, de Groot RR, van Romunde LK, Hofman AP. Risk of dementia in patients with Parkinson's disease, epilepsy, and severe head trauma: a register-based follow-up study. Am J Epidemiol 1995; 142: 1300-1305.
24. Glatt SL, Hubble JP, Lyons K, et al. Risk factors for dementia in Parkinson's disease: effect of education. Neuroepidemiology 1996; 15: 20-25.
25. Levy G, Schupf N, Tang MX, et al. Combined effect of age and severity on the risk of dementia in Parkinson's disease. Ann Neurol 2002; 51: 722-729.
26. Diamond SG, Markham CH, Hoehn MM, McDowell FH, Muenter MD. An examination of male-female differences in progression and mortality of Parkinson's disease. Neurology 1990; 40: 763-766.
27. Marder K, Flood P, Cote L, Mayeux R. A pilot study of risk factors for dementia in Parkinson's disease. Mov Disord 1990; 5: 156-161.
28. Marder K, Tang MX, Alfaro B, et al. Risk of Alzheimer's disease in relatives of Parkinson's disease patients with and without dementia. Neurology 1999; 52: 719-724.
29. Starkstein SE, Mayberg HS, Leiguarda R, Preziosi TJ, Robinson RGP. A prospective longitudinal study of depression, cognitive decline, and physical impairments in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 1992; 55: 377-382.
30. Emre M, Aarsland D, Brown R, et al. Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord 2007; 22: 1689-1707; quiz1837.
31. Marinus J, Visser M, Verwey NA, et al. Assessment of cognition in Parkinson's disease. Neurology 2003; 61: 1222-1228.
32. Verbaan D, Marinus J, Visser M, et al. Cognitive impairment in Parkinson's disease. J Neurol Neurosurg Psychiatry 2007; 78: 1182-1187.
33. Athey RJ, Porter RW, Walker RW. Cognitive assessment of a representative community population with Parkinson's disease (PD) using the Cambridge Cognitive Assessment-Revised (CAMCOG-R). Age Ageing 2005; 34: 268-273.
34. Nasreddine ZS, Phillips NA, Bedirian V, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc 2005; 53: 695-699.
35. Kalbe E, Calabrese P, Kohn N, et al. Screening for cognitive deficits in Parkinson's disease with the Parkinson neuropsychometric dementia assessment (PANDA) instrument. Parkinsonism Relat Disord 2008; 14: 93-101.
36. Folstein MF, Folestein SE, McHugh PR. Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-198.
37. Petersen RC. Mild cognitive impairment: current research and clinical implications. Semin Neurol 2007; 27: 22-31.
38. Petersen RC, Doody R, Kurz A, et al. Current concepts in mild cognitive impairment. Arch Neurol 2001; 58: 1985-1992.
39. Muslimovic D, Post B, Speelman JD, Schmand B. Cognitive profile of patients with newly diagnosed Parkinson disease. Neurology 2005; 65: 1239-1245.
40. Dujardin K, Degreef JF, Rogelet P, Defebvre L, Destee A. Impairment of the supervisory attentional system in early untreated patients with Parkinson's disease. J Neurol 1999; 246: 783-788.
41. Cooper JA, Sagar HJ, Jordan N, Harvey NS, Sullivan EV. Cognitive impairment in early, untreated Parkinson's disease and its relationship to motor disability. Brain 1991; 114 (Part 5): 2095-2122.
42. Hughes AJ, Ben-Shlomo Y, Daniel SE, Lees AJP. What features improve the accuracy of clinical diagnosis in Parkinson's disease: a clinicopathologic study. Neurology 1992; 42: 1142-1146.
43. Hughes AJ, Daniel SE, Blankson S, Lees AJ. A clinicopathologic study of 100 cases of Parkinson's disease. Arch Neurol 1993; 50: 140-148.
44. Pagonabarraga J, Kulisevsky J, Llebaria G, Garcia-Sanchez C, Pascual-Sedano B, Gironell A. Parkinson's disease-cognitive rating scale: a new cognitive scale specific for Parkinson's disease. Mov Disord 2008; 23: 998-1005.
45. Gill DJ, Freshman A, Blender JA, Ravina B. The Montreal cognitive assessment as a screening tool for cognitive impairment in Parkinson's disease. Mov Disord 2008; 23: 1043-1046.
46. Caviness JN, Driver-Dunckley E, Connor DJ, et al. Defining mild cognitive impairment in Parkinson's disease. Mov Disord 2007; 22: 1272-1277.
47. Janvin CC, Larsen JP, Aarsland D, Hugdahl K. Subtypes of mild cognitive impairment in Parkinson's disease: progression to dementia. Mov Disord 2006; 21: 1343-1349.
48. Williams-Gray CH, Foltynie T, Brayne CE, Robbins TW, Barker RA. Evolution of cognitive dysfunction in an incident Parkinson's disease cohort. Brain 2007; 130 (Part 7): 1787-1798.
49. Stern Y, Richards M, Sano M, Mayeux RP. Comparison of cognitive changes in patients with Alzheimer's and Parkinson's disease. Arch Neurol 1993; 50: 1040-1045.
50. Dubois B, Burn D, Goetz C, et al. Diagnostic procedures for Parkinson's disease dementia: recommendations from the movement disorder society task force. Mov Disord 2007; 22: 2314-2324.
51. Voon V, Kubu C, Krack P, Houeto JL, Troster AI. Deep brain stimulation: neuropsychological and neuropsychiatric issues. Mov Disord 2006; 21 ( Suppl 14): S305-S327.
52. Parsons TD, Rogers SA, Braaten AJ, Woods SP, Troster AI. Cognitive sequelae of subthalamic nucleus deep brain stimulation in Parkinson's disease: a meta-analysis. Lancet Neurol 2006; 5: 578-588.
53. Contarino MF, Daniele A, Sibilia AH, et al. Cognitive outcome 5 years after bilateral chronic stimulation of subthalamic nucleus in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 2007; 78: 248-252.
54. Aybek S, Gronchi-Perrin A, Berney A, et al. Long-term cognitive profile and incidence of dementia after STN-DBS in Parkinson's disease. Mov Disord 2007; 22: 974-981.
55. Bohnen NI, Kaufer DI, Ivanco LS, et al. Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic study. Arch Neurol 2003; 60: 1745-1748.
56. Bohnen NI, Kaufer DI, Hendrickson R, et al. Cognitive correlates of cortical cholinergic denervation in Parkinson's disease and parkinsonian dementia. J Neurol 2006; 253: 242-247.
57. Hilker R, Thomas AV, Klein JC, et al. Dementia in Parkinson disease: functional imaging of cholinergic and dopaminergic pathways. Neurology 2005; 65: 1716-1722.
58. Huang C, Mattis P, Tang C, Perrine K, Carbon M, Eidelberg D. Metabolic brain networks associated with cognitive function in Parkinson's disease. Neuroimage 2007; 34: 714-723.
59. Huang C, Tang C, Feigin A, et al. Changes in network activity with the progression of Parkinson's disease. Brain 2007; 130 (Part 7): 1834-1846.
60. Lippa CF, Duda JE, Grossman M, et al. DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers. Neurology 2007; 68: 812-819.
61. Levy G, Louis ED, Mejia-Santana H, et al. Lack of familial aggregation of Parkinson disease and Alzheimer disease. Arch Neurol 2004; 61: 1033-1039.
62. Elbaz A, Grigoletto F, Baldereschi M, et al. Familial aggregation of Parkinson's disease: a population-based case-control study in Europe.EUROPARKINSON Study Group. Neurology 1999; 52: 1876-1882.
63. Arai H, Muramatsu T, Higuchi S, Sasaki H, Trojanowski JQ. Apolipoprotein E gene in Parkinson's disease with or without dementia. Lancet 1994; 344: 889.
64. Parsian A, Racette B, Goldsmith LJ, Perlmutter JS. Parkinson's disease and apolipoprotein E: possible association with dementia but not age at onset. Genomics 2002; 79: 458-461.
65. Pankratz N, Byder L, Halter C, et al. Presence of an APOE4 allele results in significantly earlier onset of Parkinson's disease and a higher risk with dementia. Mov Disord 2006; 21: 45-49.
66. Marder K, Maestre G, Cote L, et al. The apolipoprotein epsilon 4 allele in Parkinson's disease with and without dementia. Neurology 1994; 44: 1330-1331.
67. Koller WC, Glatt SL, Hubble JP, et al. Apolipoprotein E genotypes in Parkinson's disease with and without dementia. Ann Neurol 1995; 37: 242-245.
68. Inzelberg R, Chapman J, Treves TA, et al. Apolipoprotein E4 in Parkinson disease and dementia: new data and meta-analysis of published studies. Alzheimer Dis Assoc Disord 1998; 12: 45-48.
69. Whitehead AS, Bertrandy S, Finnan F, Butler A, Smith GD, Ben-Shlomo Y. Frequency of the apolipoprotein E epsilon 4 allele in a case-control study of early onset Parkinson's disease. J Neurol Neurosurg Psychiatry 1996; 61: 347-351.
70. Mattila PM, Koskela T, Roytta M, et al. Apolipoprotein E epsilon4 allele frequency is increased in Parkinson's disease only with co-existing Alzheimer pathology. Acta Neuropathol (Berl) 1998; 96: 417-420.
71. Huang X, Chen P, Kaufer DI, Troster AI, Poole C. Apolipoprotein E and dementia in Parkinson disease: a meta-analysis. Arch Neurol 2006; 63: 189-193.
72. Egensperger R, Bancher C, Kosel S, Jellinger K, Mehraein P, Graeber MB. The apolipoprotein E epsilon 4 allele in Parkinson's disease with Alzheimer lesions. Biochem Biophys Res Commun 1996; 224: 484-486.
73. Harhangi BS, de Rijk MC, van Duijn CM, Van Broeckhoven C, Hofman A, Breteler MM. APOE and the risk of PD with or without dementia in a population-based study. Neurology 2000; 54: 1272-1276.
74. Zarranz JJ, Alegre J, Gomez-Esteban JC, et al. The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann Neurol 2004; 55: 164-173.
75. Farrer M, Kachergus J, Forno L, et al. Comparison of kindreds with parkinsonism and alpha-synuclein genomic multiplications. Ann Neurol 2004; 55: 174-179.
76. Haugarvoll K, Uitti RJ, Farrer MJ, Wszolek ZK. LRRK2 gene and tremor-dominant parkinsonism. Arch Neurol 2006; 63: 1346-1347.
77. Saunders-Pullman R, Lipton RB, Senthil G, et al. Increased frequency of the LRRK2 G2019S mutation in an elderly Ashkenazi Jewish population is not associated with dementia. Neurosci Lett 2006; 402: 92-96.
78. Goldwurm S, Zini M, Di Fonzo A, et al. LRRK2 G2019S mutation and Parkinson's disease: a clinical, neuropsychological and neuropsychiatric study in a large Italian sample. Parkinsonism Relat Disord 2006; 12: 410-419.
79. Benbunan BR, Korczyn AD, Giladi N. Parkin mutation associated parkinsonism and cognitive decline, comparison to early onset Parkinson's disease. J Neural Transm 2004; 111: 47-57.
80. Goris A, Williams-Gray CH, Clark GR, et al. Tau and alpha-synuclein in susceptibility to, and dementia in, Parkinson's disease. Ann Neurol 2007; 62: 145-153.
81. Bonifati V. Recent advances in the genetics of dementia with lewy bodies. Curr Neurol Neurosci Rep 2008; 8: 187-189.
82. Lwin A, Orvisky E, Goker-Alpan O, LaMarca ME, Sidransky E. Glucocerebrosidase mutations in subjects with parkinsonism. Mol Genet Metab 2004; 81: 70-73.
83. Aharon-Peretz J, Rosenbaum H, Gershoni-Baruch R. Mutations in the glucocerebrosidase gene and Parkinson's disease in Ashkenazi Jews. N Engl J Med 2004; 351: 1972-1977.
84. Clark LN, Ross BM, Wang Y, et al. Mutations in the glucocerebrosidase gene are associated with early-onset Parkinson disease. Neurology 2007; 69: 1270-1277.
85. Gan-Or Z, Giladi N, Rozovski U, et al. Genotype-phenotype correlations between GBA mutations and Parkinson disease risk and onset. Neurology 2008; 70: 2277-2283.
86. Goker-Alpan O, Giasson BI, Eblan MJ, et al. Glucocerebrosidase mutations are an important risk factor for Lewy body disorders. Neurology 2006; 67: 908-910.
87. Morens DM, Grandinetti A, Reed D, White LR, Ross GWP. Cigarette smoking and protection from Parkinson's disease: false association or etiologic clue? Neurology 1995; 45: 1041-1051.
88. Ebmeier KP, Calder SA, Crawford JR, Stewart L, Besson JA, Mutch WJ. Mortality and causes of death in idiopathic Parkinson's disease: results from the Aberdeen whole population study. Scott Med J 1990; 35: 173-175.
89. Levy G, Tang MX, Cote LJ, et al. Do risk factors for Alzheimer's disease predict dementia in Parkinson's disease? An exploratory study. Mov Disord 2002; 17: 250-257.
90. Marder K, Tang MX, Alfaro B, et al. Postmenopausal estrogen use and Parkinson's disease with and without dementia. Neurology 1998; 50: 1141-1143.
91. Maidment I, Fox C, Boustani M. Cholinesterase inhibitors for Parkinson's disease dementia. Cochrane Database Syst Rev 2006: CD004747.
92. Emre M, Aarsland D, Albanese A, et al. Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med 2004; 351: 2509-2518.
93. Mattis SP. Mental status examination for organic mental syndrome in the elderly patient. In: Bellak L, Karasu T, editors. Geriatric psychiatry. New York: Grune & Stratton, 1976. p 77-121.
94. Ravina B, Putt M, Siderowf A, et al. Donepezil for dementia in Parkinson's disease: a randomised, double blind, placebo controlled, crossover study. J Neurol Neurosurg Psychiatry 2005; 76: 934-939.
95. Hutchinson M, Fazzini EP. Cholinesterase inhibition in Parkinson's disease. J Neurol Neurosurg Psychiatry 1996; 61: 324-325.
96. Aarsland D, Laake K, Larsen JP, Janvin CP. Donepezil for cognitive impairment in Parkinson's disease: a randomised controlled study. J Neurol Neurosurg Psychiatry 2002; 72: 708-712.
97. Bergman J, Lerner VP. Successful use of donepezil for the treatment of psychotic symptoms in patients with Parkinson's disease. Clin Neuropharmacol 2002; 25: 107-110.
98. Fabbrini G, Barbanti P, Aurilia C, Pauletti C, Lenzi GL, Meco GP. Donepezil in the treatment of hallucinations and delusions in Parkinson's disease. Neurol Sci 2002; 23: 41-43.
99. Korczyn AD, Giladi NP. Acetylcholinesterase inhibitors in the treatment of dementia in Parkinson's disease. In: Bedard M-A, Agid Y, Chouinard S, Fahn S, Korczyn AD, Lesperance P, editors. Mental and behavioral dysfunction in movement disorders. Totowa, NJ: Humana Press; 2003. p 295-301.
100. Reading PJ, Luce AK, McKeith IGP. Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment: preliminary findings from an open trial. Mov Disord 2001; 16: 1171-1174.
101. Aarsland D, Hutchinson MP. Galantamine for Parkinson's disease with dementia. Eur Neuropsychopharm 2002; 12 ( Suppl 12): S378-S379.
102. Poewe W, Wolters E, Emre M, et al. Long-term benefits of rivastigmine in dementia associated with Parkinson's disease: an active treatment extension study. Mov Disord 2006; 21: 456-461.
103. Burn D, Emre M, McKeith I, et al. Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease. Mov Disord 2006; 21: 1899-1907.
104. Inzelberg R, Bonuccelli U, Schechtman E, et al. Association between amantadine and the onset of dementia in Parkinson's disease. Mov Disord 2006; 21: 1375-1379.